Skip to main content
Top
Published in: Diabetes Therapy 2/2016

Open Access 01-06-2016 | Original Research

Clinical Effectiveness and Safety of Analog Glargine in Type 1 Diabetes: A Systematic Review and Meta-Analysis

Authors: Lays P. Marra, Vania E. Araújo, Thales B. C. Silva, Leonardo M. Diniz, Augusto A. Guerra Junior, Francisco A. Acurcio, Brian Godman, Juliana Álvares

Published in: Diabetes Therapy | Issue 2/2016

Login to get access

Abstract

Introduction

The use of insulin analogs for the treatment of type 1 diabetes mellitus (T1DM) is widespread; however, the therapeutic benefits still require further evaluation given their higher costs. The objective of this study was to evaluate the effectiveness and safety of analog insulin glargine compared to recombinant DNA (rDNA) insulin in patients with T1DM in observational studies, building on previous reviews of randomized controlled trials comparing neutral protamine Hagedorn insulin and insulin glargine.

Methods

A systematic review with a meta-analysis was performed. The review included cohort studies and registries available on PubMed, LILACS, and the Cochrane Central Register of Controlled Trials (CENTRAL), as well as manual and gray literature searches. The meta-analysis was conducted in Review Manager 5.3 software. The primary outcomes were glycated hemoglobin (Hb1Ac), weight gain, and hypoglycemia. Methodological quality was assessed using the Newcastle-Ottawa scale.

Results

Out of 796 publications, 11 studies were finally included. The meta-analysis favored insulin glargine in HbA1c outcomes (adult patients) and hypoglycemic episodes (P < 0.05), but without reaching glycemic control (Hb1Ac to approximately 7%). The methodological quality of the studies was moderate, noting that 45% of studies were funded by pharmaceutical companies.

Conclusion

Given the high heterogeneity of the studies, the discrete value presented by the estimated effect on effectiveness and safety, potential conflicts of interest of the studies, and the appreciable higher cost of insulin glargine, there is still no support for recommending first-line therapy with analogs. The role of analogs in the treatment of T1DM could be better determined by further observational studies of good methodological quality to assess their long-term effectiveness and safety, as well as their cost-effectiveness.
Literature
1.
go back to reference Pasqualotto KR, Alberton D, Frigeri HR. Diabetes mellitus and complications. J Biotechnol Biodivers. 2012;3(4):134–45. Pasqualotto KR, Alberton D, Frigeri HR. Diabetes mellitus and complications. J Biotechnol Biodivers. 2012;3(4):134–45.
2.
go back to reference Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetica and pharmacodynamics of subcutaneous injection of long-acting human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142–8.CrossRefPubMed Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetica and pharmacodynamics of subcutaneous injection of long-acting human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142–8.CrossRefPubMed
3.
go back to reference Caires de Souza AL, de Assis Acurcio F, Guerra Júnior AA, Rezende Macedodo Nascimento RC, Godman B, Diniz LM. Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review. Appl Health Econ Health Policy. 2014;12(1):19–32.CrossRefPubMed Caires de Souza AL, de Assis Acurcio F, Guerra Júnior AA, Rezende Macedodo Nascimento RC, Godman B, Diniz LM. Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review. Appl Health Econ Health Policy. 2014;12(1):19–32.CrossRefPubMed
5.
go back to reference American Diabetes Association. Standards of medical care in diabetes. Position statement. Diabetes Care. 2007;30(Suppl. 1):S4–41.CrossRef American Diabetes Association. Standards of medical care in diabetes. Position statement. Diabetes Care. 2007;30(Suppl. 1):S4–41.CrossRef
6.
go back to reference Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000;23(5):644–9.CrossRefPubMed Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000;23(5):644–9.CrossRefPubMed
7.
go back to reference Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA1c analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care. 2002;25(2):275–8.CrossRefPubMed Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA1c analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care. 2002;25(2):275–8.CrossRefPubMed
8.
go back to reference Sanches ACC, Correr CJ, Venson R, et al. Insulin analogues versus human insulin in type 1 diabetes: direct and indirect meta-analyses of efficacy and safety. Braz J Pharm Sci. 2013;49(3):501–9.CrossRef Sanches ACC, Correr CJ, Venson R, et al. Insulin analogues versus human insulin in type 1 diabetes: direct and indirect meta-analyses of efficacy and safety. Braz J Pharm Sci. 2013;49(3):501–9.CrossRef
11.
go back to reference Szypowska A, Golicki D, Groele L, Pańkowska E. Long-acting insulin analogue detemir compared with NPH insulin in type 1 diabetes. Pol Arch Med Wewn. 2011;121:237–46.PubMed Szypowska A, Golicki D, Groele L, Pańkowska E. Long-acting insulin analogue detemir compared with NPH insulin in type 1 diabetes. Pol Arch Med Wewn. 2011;121:237–46.PubMed
12.
go back to reference Schreiber SA, Russmann A. Long-term efficacy of insulin glargine therapy with an educational programme in type 1 diabetes patients in clinical practice. Curr Med Res Opin. 2007;23(12):3131–6.CrossRefPubMed Schreiber SA, Russmann A. Long-term efficacy of insulin glargine therapy with an educational programme in type 1 diabetes patients in clinical practice. Curr Med Res Opin. 2007;23(12):3131–6.CrossRefPubMed
13.
go back to reference Johansen OE. VanbergPJ, Kilhovd BK, Jørgensen AP. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia. Vasc Health Risk Manag. 2009;5(1):121–8.PubMedCentralPubMed Johansen OE. VanbergPJ, Kilhovd BK, Jørgensen AP. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia. Vasc Health Risk Manag. 2009;5(1):121–8.PubMedCentralPubMed
14.
go back to reference Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–12.CrossRefPubMed Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–12.CrossRefPubMed
15.
go back to reference Hartling L, Hamm M, Milne A, et al. Validity and inter rater reliability testing of quality assessment instruments [internet]. Appendix E, decision rules for application of the Newcastle-Ottawa Scale. Agency for Healthcare Research and Quality (US), Rockville (MD). Available from: http://www.ncbi.nlm.nih.gov/books/NBK92291/. 2012. Hartling L, Hamm M, Milne A, et al. Validity and inter rater reliability testing of quality assessment instruments [internet]. Appendix E, decision rules for application of the Newcastle-Ottawa Scale. Agency for Healthcare Research and Quality (US), Rockville (MD). Available from: http://​www.​ncbi.​nlm.​nih.​gov/​books/​NBK92291/​. 2012.
16.
go back to reference Higgins JPT, et al., editors. Cochrane handbook for systematic reviews of interventions. Chichester: Wiley-Blackwell; 2008. Higgins JPT, et al., editors. Cochrane handbook for systematic reviews of interventions. Chichester: Wiley-Blackwell; 2008.
17.
go back to reference Garg SK, Paul JM, Karsten JI, Menditto L, Gottlieb PA. Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes. Diabetes Technol Ther. 2004;6(5):589–95.CrossRefPubMed Garg SK, Paul JM, Karsten JI, Menditto L, Gottlieb PA. Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes. Diabetes Technol Ther. 2004;6(5):589–95.CrossRefPubMed
18.
go back to reference Yamamoto-Honda R, Takahashi Y, Yoshida Y, et al. Use of insulin glargine in japanese patients with type 1 diabetes. Intern Med. 2007;46(13):937–43.CrossRefPubMed Yamamoto-Honda R, Takahashi Y, Yoshida Y, et al. Use of insulin glargine in japanese patients with type 1 diabetes. Intern Med. 2007;46(13):937–43.CrossRefPubMed
19.
go back to reference Colino E, López-Capapé M, Golmayo L, Alvarez MA, Alonso M, Barrio R. Therapy with insulin glargine (Lantus1) in toddlers, children and adolescents with type 1 diabetes. Diabetes Res Clin Pract. 2005;70(1):1–7.CrossRefPubMed Colino E, López-Capapé M, Golmayo L, Alvarez MA, Alonso M, Barrio R. Therapy with insulin glargine (Lantus1) in toddlers, children and adolescents with type 1 diabetes. Diabetes Res Clin Pract. 2005;70(1):1–7.CrossRefPubMed
20.
go back to reference Dixon B, Chase HP, Burdick J, et al. Use of insulin glargine in children under age 6 with type 1 diabetes. Pediatr Diabetes. 2005;6(3):150–4.CrossRefPubMed Dixon B, Chase HP, Burdick J, et al. Use of insulin glargine in children under age 6 with type 1 diabetes. Pediatr Diabetes. 2005;6(3):150–4.CrossRefPubMed
21.
go back to reference Hathout EH, Fujishige L, Geach J, Ischandar M, Maruo S, Mace JW. Effect of therapy with insulin glargine (Lantus®) on glycemic control in toddlers, children, and adolescents with diabetes. Diabetes Technol Ther. 2003;5(5):801–6.CrossRefPubMed Hathout EH, Fujishige L, Geach J, Ischandar M, Maruo S, Mace JW. Effect of therapy with insulin glargine (Lantus®) on glycemic control in toddlers, children, and adolescents with diabetes. Diabetes Technol Ther. 2003;5(5):801–6.CrossRefPubMed
22.
go back to reference Päivärinta M, Tapanainen P, Veijola R. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2008;9:83–90.CrossRefPubMed Päivärinta M, Tapanainen P, Veijola R. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2008;9:83–90.CrossRefPubMed
23.
go back to reference Salemyr J, Bangand P, Örtqvist E. Lower HbA1c after 1 year, in children withtype1 diabetes treated with insulin glargine vs. NPH insulin from diagnosis: a retrospective study. Pediatr Diabetes. 2011;12(5):501–5.CrossRefPubMed Salemyr J, Bangand P, Örtqvist E. Lower HbA1c after 1 year, in children withtype1 diabetes treated with insulin glargine vs. NPH insulin from diagnosis: a retrospective study. Pediatr Diabetes. 2011;12(5):501–5.CrossRefPubMed
24.
go back to reference Herwig J, Schöll-Schilling G, Böhles H. Glycaemic control and hypoglycaemia in children, adolescents and young adults with unstable type 1 diabetes mellitus treated with insulin glargine or intermediate-acting insulin. J Pediatr Endocrinol Metab. 2007;20(4):517–25.CrossRefPubMed Herwig J, Schöll-Schilling G, Böhles H. Glycaemic control and hypoglycaemia in children, adolescents and young adults with unstable type 1 diabetes mellitus treated with insulin glargine or intermediate-acting insulin. J Pediatr Endocrinol Metab. 2007;20(4):517–25.CrossRefPubMed
25.
go back to reference Haukka J, Hoti F, Erästö P, Saukkonen T, Mäkimattila S, Korhonen P. Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study. Pharmacoepidemiol Drug Saf. 2013;22(12):1326–35.CrossRefPubMedCentralPubMed Haukka J, Hoti F, Erästö P, Saukkonen T, Mäkimattila S, Korhonen P. Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study. Pharmacoepidemiol Drug Saf. 2013;22(12):1326–35.CrossRefPubMedCentralPubMed
26.
go back to reference Marley J. Efficacy, effectiveness, efficiency. Aust Prescr. 2000;23:114–5.CrossRef Marley J. Efficacy, effectiveness, efficiency. Aust Prescr. 2000;23:114–5.CrossRef
27.
go back to reference Pereira C, Veiga N. Educação Para a Saúde Baseada em Evidências. 2014. Pereira C, Veiga N. Educação Para a Saúde Baseada em Evidências. 2014.
28.
go back to reference Malmström RE, Godman BB, Diogene E, et al. Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol. 2013;14(4):39. Malmström RE, Godman BB, Diogene E, et al. Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol. 2013;14(4):39.
29.
go back to reference Oliveira JEPD, Vencio S. Diretrizes da Sociedade Brasileira de Diabetes: 2014-2015. Sa˜o Paulo: AC Farmacêutica, 2015, pp. 1–360. Oliveira JEPD, Vencio S. Diretrizes da Sociedade Brasileira de Diabetes: 2014-2015. Sa˜o Paulo: AC Farmacêutica, 2015, pp. 1–360.
30.
go back to reference Warren E, Weatherley-Jones E, Chilcott J, Beverley C. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess. 2004;8(45):iii, 1–57. Warren E, Weatherley-Jones E, Chilcott J, Beverley C. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess. 2004;8(45):iii, 1–57.
31.
go back to reference Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev. 2006;2:CD003287.PubMed Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev. 2006;2:CD003287.PubMed
32.
go back to reference Netto AP, Andriolo A, Filho FF, et al. Atualização sobre hemoglobina glicada (HbA1C) para avaliação do controle glicêmico e para o diagnóstico do diabetes: aspectos clínicos e laboratoriais. J Bras Patol Med Lab. 2009;45(1):31–48. Netto AP, Andriolo A, Filho FF, et al. Atualização sobre hemoglobina glicada (HbA1C) para avaliação do controle glicêmico e para o diagnóstico do diabetes: aspectos clínicos e laboratoriais. J Bras Patol Med Lab. 2009;45(1):31–48.
33.
go back to reference Sacks DB. Hemoglobin variants and hemoglobin A1c analysis: problem solved? Clin Chem. 2003;49:1245–7.CrossRefPubMed Sacks DB. Hemoglobin variants and hemoglobin A1c analysis: problem solved? Clin Chem. 2003;49:1245–7.CrossRefPubMed
34.
go back to reference Vardi M, Jacobson E, Nini A, Bitterman H. Intermediate acting versus long acting insulin for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2008;16(3):CD006297. Vardi M, Jacobson E, Nini A, Bitterman H. Intermediate acting versus long acting insulin for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2008;16(3):CD006297.
35.
36.
go back to reference Ggoldim JR. Conflito de interesses na área da saúde. 2007. Ggoldim JR. Conflito de interesses na área da saúde. 2007.
37.
38.
go back to reference Civaner M. Sale strategies of pharmaceutical companies in a “pharmerging” country: the problems will not improve if the gaps remain. Health Policy. 2012;106:225–32.CrossRefPubMed Civaner M. Sale strategies of pharmaceutical companies in a “pharmerging” country: the problems will not improve if the gaps remain. Health Policy. 2012;106:225–32.CrossRefPubMed
39.
go back to reference Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289(4):454–65.CrossRefPubMed Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289(4):454–65.CrossRefPubMed
40.
go back to reference Ross JS, Tse T, Zarin DA, Xu H, Zhou L, Krumholz HM. Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. BMJ. 2012;344(d7292):1–10. Ross JS, Tse T, Zarin DA, Xu H, Zhou L, Krumholz HM. Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. BMJ. 2012;344(d7292):1–10.
41.
go back to reference Pereira MG, Galvão TF. Heterogeneidade e viés de publicação em revisões sistemáticas. Epidemiologia e Serviços de Saúde. 2014;23(4):775–8.CrossRef Pereira MG, Galvão TF. Heterogeneidade e viés de publicação em revisões sistemáticas. Epidemiologia e Serviços de Saúde. 2014;23(4):775–8.CrossRef
42.
go back to reference Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry. 2006;163(2):185–94.CrossRefPubMed Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry. 2006;163(2):185–94.CrossRefPubMed
43.
go back to reference Wang F, Carabino JM, Vergara CM. Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther. 2003;25(6):1541–77.CrossRefPubMed Wang F, Carabino JM, Vergara CM. Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther. 2003;25(6):1541–77.CrossRefPubMed
Metadata
Title
Clinical Effectiveness and Safety of Analog Glargine in Type 1 Diabetes: A Systematic Review and Meta-Analysis
Authors
Lays P. Marra
Vania E. Araújo
Thales B. C. Silva
Leonardo M. Diniz
Augusto A. Guerra Junior
Francisco A. Acurcio
Brian Godman
Juliana Álvares
Publication date
01-06-2016
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 2/2016
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-016-0166-y

Other articles of this Issue 2/2016

Diabetes Therapy 2/2016 Go to the issue